Results 221 to 230 of about 534,439 (293)

Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study. [PDF]

ERJ Open Res
Zemanick ET, McColley SA, Linnemann RW, Rayment JH, Harris WT, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Sosnay PR, Ahluwalia N, Liu L, Jennings M, Rosenfeld M.   +14 more
europepmc   +1 more source

SAHA increases chaperone expression and reduces Z-alpha-1-antitrypsin polymers in a patient specific iPSC-based liver model for alpha-1-antitrypsin deficiency. [PDF]

Stem Cell Res Ther
Graffmann N, Hokamp R, Lörch C, Fromme M, Wruck W, Strnad P, Adjaye J.   +6 more
europepmc   +1 more source

Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure: The FINEARTS-HF Randomized Clinical Trial.

JAMA Cardiol
Ostrominski JW, Mc Causland FR, Claggett BL, Desai AS, Jhund PS, Henderson A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Amarante F, Brinker M, Schloemer P, Rohwedder K, McMurray JJV, Solomon SD, Vaduganathan M.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biocatalysis for the synthesis of pharmaceuticals and pharmaceutical intermediates

Bioorganic & Medicinal Chemistry, 2018
Biocatalysis has been increasingly used for pharmaceutical synthesis in an effort to make manufacturing processes greener and more sustainable. Biocatalysts that possess excellent activity, specificity, thermostability and solvent-tolerance are highly sought after to meet the requirements of practical applications.
Huihua Sun, Hongfang Zhang, Ee Lui Ang, Huimin Zhao   +3 more
openaire   +2 more sources